CORE--CLINICAL INVESTIGATIONS

加州大学洛杉矶分校CFAR临床研究核心旨在促进 HIV临床感染与其相关恶性病变的相互作用 并发症。核心利用了主任在 卡波西肉瘤的发病机制和免疫基础治疗 免疫缺陷患者临床试验的临床资料 干扰素、白介素2、白介素4等调节剂 白介素12试验。通过促进Basic之间的紧密接口 科学家和临床医生，成本效益高和富有成效的研究通常 结果。核心提供四项基本服务： 1.为科学家和基础研究人员提供后勤支持 进一步了解集合性肺炎的免疫发病机制 患者的临床标本包括血清、血浆、脊髓液和 其他非恶性体液。 2.获取非恶性储存的临床标本，包括获取 患者独特的免疫调节剂或基因临床标本 用于回顾性研究的治疗试验。 3.提供咨询支持，包括协助向 未来标本的机构审查委员会，以及 4.维持现有标本的电脑化资料库，方便 取回。 该岩芯目前有超过40,000个可用的样本，并与 4,000多名患者的临床信息。核心继续收购 每年有超过1,000个新样品。1996年，8名调查人员处理或 从岩芯中获得了5230个样本。核心提供了它的大部分 以充值方式为用户提供核心设施的服务 以最具成本效益的方式存储、处理和检索 保存的标本。希望通过鼓励基础科学家 使用临床材料进行研究，体外观察可以 迅速转化为临床试验，理想的是改善了治疗方法 爱滋病毒。该核心不提供临床试验支持。

The UCLA CFAR Clinical Investigations Core is designed to facilitate interactions between clinical HIV infection and its related malignant complications. The core utilizes the expertise of the director in the pathogenesis of Kaposi sarcoma and immune based therapy and accesses the clinical materials generated from clinical trials of patients with immune modulating agents such as interferons, interleukin-2, interleukin-4, and interleukin-12 trials. By facilitating a close interface between basic scientists and clinicians, cost effective and productive studies often result. The core provides four basic services: 1. logistical support for the scientists and basic researchers that further our understanding of the immunopathogenesis of collection of clinical specimens from patients including serum, plasma, spinal fluid and other non-malignant body fluids. 2. access to non-malignant stored clinical specimens including access to unique clinical specimens from patients on immune modulator or gene therapy trials for retrospective studies. 3. consultative support including assistance with applications to the institutional review board for prospective specimens, and 4. maintains a computerize data base of existing specimens for easy retrieval. The core currently has over 40,000 specimens available and has correlative clinical information on over 4,000 patients. The core continues to acquire over 1,000 new samples per year. In 1996, eight investigators processed or obtained 5,230 samples from the core. The core provides the bulk of its services on a re-charge basis providing users with a core facility that is the most cost effective approach for storage, processing and retrieval of stored specimens. It is hoped that by encouraging basic scientists to perform studies using clinical materials, in vitro observations can be rapidly translated into clinical trials and, ideally improved therapy for HIV. This core does not provide clinical trials support.